This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.
Acadia Healthcare (ACHC) Buys Real Estate to Expand in Chicago
by Zacks Equity Research
Acadia Healthcare (ACHC) purchases real estate in Illinois to serve the local communities with better healthcare facilities.
Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M
by Zacks Equity Research
Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.
3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022
by Debanjana Dey
Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.
Ensign Group (ENSG) Hikes Dividend to Share More Profits
by Zacks Equity Research
Ensign Group's (ENSG) dividend hike reflects its intention to enhance shareholders' value supported by its strong financial position.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Accuray's (ARAY) CyberKnife System Gets Shonin Approval
by Zacks Equity Research
Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.
Here's Why You Should Retain Ecolab (ECL) Stock Right Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction from a solid product portfolio and segmental strength. However, segmental weakness remains a woe.
Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering
by Zacks Equity Research
Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.
DENTSPLY SIRONA's (XRAY) New Alliance to Boost Digital Dentistry
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) and 3Shape extend their partnership to simplify digitally oriented workflows for dentists and dental technicians.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.
NextGen's (NXGN) Integrated Platform Gets Adopted by Monmouth
by Zacks Equity Research
NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology's (ALGN) better-than-expected results and growing uptake of iTero scanners in the third quarter of fiscal 2021.
Medtronic (MDT) Gets Health Canada License for Hugo RAS System
by Zacks Equity Research
The receipt of the Health Canada license for Medtronic's (MDT) Hugo RAS System is likely to enhance accessibility to robotic-assisted surgery in Canada.
QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay
by Zacks Equity Research
QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.
Change Healthcare (CHNG) Cloud-Native PACS Now in Clinical Use
by Zacks Equity Research
The clinical use of Change Healthcare's (CHNG) cloud-native Stratus Imaging PACS is likely to enhance radiologists' productivity.
Here's Why You Should Retain IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.
Bruker (BRKR) Assay to Offer Reliable Omicron Variant Detection
by Zacks Equity Research
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.
NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout
by Zacks Equity Research
NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.
Walgreens Boots (WBA) Faces Margin Pressure, Solvency Issue
by Zacks Equity Research
Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.
Henry Schein (HSIC) Introduces Treatment Planning Software
by Zacks Equity Research
The Studio Pro 4.0 launched by Henry Schein's (HSIC) orthodontics business will enable Reveal Clear Aligners providers to personalize treatment plans with greater ease and control.
Here's Why You Should Invest in NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR.
Medtronic (MDT) Gets Health Canada License for GI Genius Module
by Zacks Equity Research
Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.